Mast cell activation syndrome — clinical presentation and diagnostic criteria

Alergologia ◽  
2021 ◽  
Vol 1 (5) ◽  
pp. 7
Author(s):  
Elena-Simona Boldeanu ◽  
Mădălina Avram ◽  
Lucian Rezmeriţă
Keyword(s):  
Mast Cell ◽  
Diagnostic Criteria ◽  
Cell Activation ◽  
Clinical Presentation ◽  
Mast Cell Activation ◽  
Mast Cell Activation Syndrome ◽  
Activation Syndrome

scholarly journals Mast cell activation syndrome: Proposed diagnostic criteria

2010 ◽  
Vol 126 (6) ◽  
pp. 1099-1104.e4 ◽  
Author(s):  
Cem Akin ◽  
Peter Valent ◽  
Dean D. Metcalfe
Keyword(s):  
Mast Cell ◽  
Diagnostic Criteria ◽  
Cell Activation ◽  
Mast Cell Activation ◽  
Mast Cell Activation Syndrome ◽  
Activation Syndrome

scholarly journals Diagnosis of mast cell activation syndrome: a global “consensus-2”

Diagnosis ◽  
2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Lawrence B. Afrin ◽  
Mary B. Ackerley ◽  
Linda S. Bluestein ◽  
Joseph H. Brewer ◽  
Jill B. Brook ◽  
...  
Keyword(s):  
Mast Cell ◽  
Mast Cells ◽  
General Population ◽  
Diagnostic Criteria ◽  
Cell Activation ◽  
Mast Cell Activation ◽  
Sustained Improvement ◽  
Mast Cell Activation Syndrome ◽  
Global Consensus ◽  
Activation Syndrome

AbstractThe concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of “mast cell activation syndrome” (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a “consensus” (re-termed here as “consensus-1”). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as “consensus-2”), resembling “consensus-1” in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by “consensus-2” criteria has potential to be problematic, but underdiagnosis by “consensus-1” criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.

Depression, psychosocial correlates, and psychosocial resources in individuals with mast cell activation syndrome

2021 ◽  
pp. 135910532110145
Author(s):  
Jennifer Nicoloro SantaBarbara ◽  
Marci Lobel
Keyword(s):  
Mast Cell ◽  
Depressive Symptoms ◽  
Cell Activation ◽  
Physical Symptoms ◽  
Mast Cell Activation ◽  
Emotional States ◽  
Mast Cell Activation Syndrome ◽  
Disease Experience ◽  
Clinically Significant ◽  
Activation Syndrome

Individuals with Mast Cell Activation Syndrome (MCAS), a rare chronic disease, experience unpredictable physical symptoms and diagnostic challenges resulting in poor emotional states. The prevalence and correlates of depressive symptoms were examined among 125 participants who completed the CES-D and relevant instruments. The majority reported a clinically-significant level of depression which was especially common among younger participants and those who reported greater loneliness or more disease-specific stressors. Greater magnitude of depressive symptoms was associated with greater illness intrusiveness, less social support, and lower optimism. Results highlight the value of interventions targeting loneliness and stressors unique to this population.

Successful targeted treatment of mast cell activation syndrome with tofacitinib

2017 ◽  
Vol 99 (2) ◽  
pp. 190-193 ◽  
Author(s):  
Lawrence B. Afrin ◽  
Roger W. Fox ◽  
Susan L. Zito ◽  
Leo Choe ◽  
Sarah C. Glover
Keyword(s):  
Mast Cell ◽  
Cell Activation ◽  
Targeted Treatment ◽  
Mast Cell Activation ◽  
Mast Cell Activation Syndrome ◽  
Activation Syndrome

P159 MAST CELL ACTIVATION SYNDROME AND MANAGEMENT OF ITS PROTEAN MANIFESTATIONS

2021 ◽  
Vol 127 (5) ◽  
pp. S49
Author(s):  
M. Hakim ◽  
D. Kurian ◽  
U. Rehman ◽  
S. Kazmi ◽  
A. Ghazi
Keyword(s):  
Mast Cell ◽  
Cell Activation ◽  
Mast Cell Activation ◽  
Mast Cell Activation Syndrome ◽  
Activation Syndrome

Adult-Onset Mast Cell Activation Syndrome Following Scombroid Poisoning a case report and review of the literature

2021 ◽  
Author(s):  
Isabelle Brock ◽  
Nicole Eng ◽  
Anne Maitland
Keyword(s):  
Mast Cell ◽  
Cell Activation ◽  
Psychiatric Symptoms ◽  
Adult Population ◽  
Relevant Literature ◽  
Mast Cell Activation ◽  
Response To Treatment ◽  
Adult Onset ◽  
Mast Cell Activation Syndrome ◽  
Activation Syndrome

Abstract Mast Cell Activation syndrome (MCAS) is a clinical condition, defined by the combination of 1) typical symptoms, 2) laboratory abnormalities and 3) response to treatment. Patients present with episodic symptoms of aberrant mast cell activation, such as abdominal cramping, asthma, hypotensive episodes, tachycardia, anaphylaxis, unexplained arrhythmias, and neurologic/psychiatric symptoms. Both clonal and nonclonal mast cell activation syndromes have been described, with a greater prevalence of non-clonal MCAS among the pediatric and adult population. Numerous extrinsic triggers of mast cell activation (MCA) are described, but recent reports point to nonatopic triggers, as the predominant, extrinsic stimulants of MCA in the adult population. The etiology of MCAS is unclear, though recent studies point to the disruption of the epithelium by infection, toxic exposures or physical trauma, and perturbation the tight regulation of these innate immune cells, associated to the epithelial borders. Here we describe a geriatric patient with adult onset MCAS, following a significant toxic exposure, scombroid poisoning. We also review the relevant literature regarding MCAS diagnosis and management as well as potential mechanisms for this hypersensitivity syndrome in adults.

scholarly journals Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report

2017 ◽  
Vol 11 (1) ◽  
Author(s):  
Faizan Malik ◽  
Naveed Ali ◽  
Syed Imran Mustafa Jafri ◽  
Ali Ghani ◽  
Mohsin Hamid ◽  
...  
Keyword(s):  
Mast Cell ◽  
Case Report ◽  
Cell Activation ◽  
Mast Cell Activation ◽  
Mast Cell Activation Syndrome ◽  
Kit D816v ◽  
Activation Syndrome
Sign in / Sign up

Export Citation Format

Share Document